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Background: Chronic Pseudomonas aeruginosa pulmonary infection is associated with a decline in lung function and reduced survival in people
with Cystic Fibrosis (CF). Damaging inﬂammatory and immunological mediators released in the lungs can be used as markers of chronic infection,
inﬂammation and lung tissue damage.
Methods: Clinical samples were collected from CF patients and healthy controls. Serum IgG and IgA anti-Pseudomonas antibodies, sputum IL-8 and
TNFα, plasma IL-6 and urine TNFr1 were measured by ELISA. Sputum neutrophil elastase (NE), cathepsin S and cathepsin B were measured by
spectrophotometric and ﬂuorogenic assays. The relationship between IgG and IgA, inﬂammatory mediators and long-term survival was determined.
Results: IgG and IL-6 positively correlated with mortality. However, multivariate analysis demonstrated that after adjusting for FEV1, IgG was not
independently related to mortality. A relationship was observed between IgG and IL-6, TNFα, TNFr1 and between IgA and IL8, cathepsin S and
cathepsin B.
Conclusions: These data indicate that biomarkers of inﬂammation are not independent predictors of survival in people with CF.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Antibody titre; Inﬂammation; Proteases; Pseudomonas aeruginosa; Cystic Fibrosis; Mortality1. Introduction
Chronic Pseudomonas aeruginosa pulmonary infection is
associated with a decline in lung function, increased exacerbations
and reduced survival in people with CF. In the lungs, chronic
infection is accompanied by airway inflammation, resulting in the
release of damaging inflammatory and immunological mediators
from a number of sources including the airway epithelium and
circulating neutrophils and macrophages [1]. Such mediators,
including neutrophil elastase (NE), IL-8 and TNFα, correlate with⁎ Corresponding author at: Centre for Infection and Immunity, Health Sciences
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http://dx.doi.org/10.1016/j.jcf.2013.06.002disease severity in diverse populations of CF patients [2–4] and
can be used as markers of chronic infection, inflammation and lung
tissue damage.
The initial humoral response to bacterial challenge in the lungs
is the production of secretory IgA (sIgA) by plasma cells in the
pulmonary mucosa, followed by the systemic release of IgG.
Antibody response to P. aeruginosa in CF can be used as a
biomarker and lung inflammation and tissue damage are related
to antibody titres [5–8]. Specific antibodies against P. aeruginosa
antigens increase when chronic infection is established and a
high number of anti-Pseudomonas precipitins have been shown
to be related to poor prognosis [5,9]. Despite increased anti-
pseudomonal antibodies, the humoral response does not confer
protective immunity against this pathogen in the CF lung [10].
In some studies, increased antibody titre against P. aeruginosa
precedes isolation of the pathogen from the respiratory tract andby Elsevier B.V. All rights reserved.
Table 1
Demographics of Cystic Fibrosis groups.
Manchester Belfast Combined
Sex, male (female) 20 (20) 37 (26) 57 (46)
CF genotype, no. (%)
F508/F508 23 (57.5) 20(31.7) 43 (41.7)
F508/other 14 (35) 24 (38.1) 38 (36.9)
Other/other 3 (7.5) 19 (30.2) 22 (21.4)
Age, y, mean (SD) 27.9 (8.5) 27.7 (8.9) 27.8 (8.7)
% FEV1, mean (SD) 44.1 (18.69) 68.0 (24.99) 58.77 (25.5)
BMI, mean (SD) 20.42 (2.71) 22.47 (4.34) 21.74 (3.94)
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than that of microbial culture [11,12]. However, this pattern
has not been consistently demonstrated and this may be due to
variation in sample collection, assay methods and microbiological
facilities available [13]. Furthermore, study results may be further
confounded by not all patients showing an early antibody response
[14]. Therefore, serological and molecular techniques may not be
particularly helpful in detection of early or intermittent colonisa-
tion. To date, there has been little agreement regarding the clinical
value of measuring serum antibody response against pathogens
such as P. aeruginosa [15], particularly in relation to CF children
[16]. Anti-pseudomonal IgG titre may have potential diagnostic
value and can be used as a prognostic tool to identify CF patients at
risk of establishing a chronic infection [17,18]. For many years this
method has been used diagnostically in the Danish CF centre in
Copenhagen to distinguish between intermittently colonised and
chronically infected patients [19].
The primary aim of this study was to determine whether
serum IgG and IgA titre against P. aeruginosa in clinically stable,
chronically infected adult CF patients correlated with mortality and
the production of host inflammatory mediators. We hypothesised
that IgG antibodies to P. aeruginosa would predict long-term
survival.
2. Methods
2.1. Patients and controls
Two separate cohorts of clinically stable CF patients were
recruited at the Manchester and Belfast Adult CF centres
[3,20]. Manchester patients were recruited over a 6-month period
between July and December 2001, and Belfast patients during the
year 2000. Data and clinical samples were collected from 63 CF
patients attending the Belfast Centre (mean age 27.7 ± 8.9 years,
37M, 26F) and from 118 age-matched healthy controls [19].
Patients from Manchester (n = 40, mean age 27.7 ± 8.3 years,
20M, 20F) were subdivided into two groups based on the
P. aeruginosa strain type causing infection: those infected
with sporadic strains and those infected with a transmissible
(P. aeruginosa strain, MA) strain. Of these 103 CF patients, 36
had no P. aeruginosa infection and 67 were chronically infected
with P. aeruginosa for at least 12 months prior to recruitment.
Both studies had ethical approval and patients and controls gave
written informed consent. Demographic and clinical data was
recorded for all CF patient cohorts at baseline including age, sex,
CF genotype, %FEV1, %FVC, white cell count (WCC), C-reactive
protein (CRP) and body mass index (BMI) (Table 1). Mortality
data was retrospectively obtained in 2013 and the time in
months until death or lung transplantation used for subsequent
analysis.
2.2. Biochemical measurements
Biochemical analysis of samples (sputum, urine, serum,
plasma) from these patients was performed as part of two
previously reported studies [3,4]. Sputum IL-8 and TNF-α,
plasma IL-6 and urine TNFr1 were measured by ELISA. SputumNE, cathepsin S and cathepsin B were measured by spectropho-
tometric and fluorogenic assays.2.3. Comparison of anti-pseudomonal immunological response
with survival
Serum samples which had been stored at −80 °C since
collection were assayed by ELISA for IgG and IgA antibodies
against P. aeruginosa antigens. Micro-titre plates (96-well)
were coated overnight with antigenic preparation from St-Ag:
1–17 (Statens Serum Institute). This antigenic preparation has
been shown to have a high sensitivity of 97% [21]. Following
blocking, diluted serum was added to each well and incubated
for 2 h at room temperature. Horseradish peroxidase conjugat-
ed anti-human IgG or IgA (DAKO Co. Golstrup, Denmark)
was added to eachwell. Optical Density was measured at 450 nM
and the titre was arbitrarily defined as ELISA units (EU) from a
standard curve developed using P. aeruginosa positive serum
(Statens Serum Institute). Samples were assayed in duplicate and
data presented as mean ± SD. The relationship between IgG and
IgA and both inflammatory mediators and survival was then
determined.2.3. Statistical analysis
Where necessary, results were log transformed to achieve
approximate normal distribution of data. A Pearson's correla-
tion coefficient was used to measure the strength of the linear
association between antibody titres, demographic/clinical
parameters and sputum inflammatory biomarkers. Immuno-
logical response in control subjects, CF patients chronically
infected with P. aeruginosa and P. aeruginosa negative CF
patients were analysed using one-way ANOVA with post-hoc
testing. The relationship between IgG and long-term survival
was determined using Cox proportional hazard modelling to
calculate hazard ratios (and 95% confidence intervals) and
allowed adjustment for individual level confounders (age, gender,
lung function and BMI). Hazard ratios (and 95% confidence
intervals) were also calculated for the association between sputum
inflammatory biomarkers and survival. Statistical analysis was
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Fig. 1. Relationship between IgG and IgA titre for patients (n = 67) chronically
colonised with P. aeruginosa. IgA and IgG results were log transformed to
achieve normal distribution of data.
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3.1. Antibody titre and demographic and clinical parameters
There was no significant difference in IgG against
P. aeruginosa antigens between the two Manchester sub-groups
(sporadic, mean 496.0 ± 548.6; transmissible, mean 492.2 ±
440.5; p = 0.64). Therefore, results from both groups (n-40
patients) were combined for further statistical analysis. By
univariate analysis (Pearson's correlation coefficient), IgG
and all clinical parameters except age were related (Table 2).
In contrast, IgA titres were only related to CRP. A significant
correlation was also observed between IgG and IgA titre for the
67 patients chronically colonised with P. aeruginosa (r = 0.609,
p b 0.001; Fig. 1).
3.2. Immunological response to chronic P. aeruginosa
colonisation
IgG and IgA titres were compared between control subjects
(n = 118), CF patients chronically colonised with P. aeruginosa
(n = 67) and P. aeruginosa negative CF patients (n = 36). There
was a significant difference in both IgG (p b 0.001, one-way
ANOVA; Fig. 2A) and IgA (p b 0.001; Fig. 2B) between the
three groups. Post-hoc testing (Tukey HSD) revealed that, for
both IgG and IgA, there was a significant difference (p b 0.001)
between control and P. aeruginosa positive patients and between
P. aeruginosa positive and negative patients but no difference
between control and P. aeruginosa negative patients (Fig. 2).
3.3. Anti-pseudomonal titre as a marker of long-term survival
Cox proportional hazard modelling was used to determine
the relationship between IgG titre and long-term survival.
Median IgG (110 ELISA units) was used to define two survival
groups with patients grouped using a categorical variable above
and below 110 (Fig. 3). There was a statistically significant
association between IgG titre and mortality (OR = 2.94, 95%
CI 1.51–5.76; p = 0.002). However, when analysis was adjusted
for all potential confounders (age, gender, lung function [FEV1]
and BMI) this association was no longer apparent (OR = 1.23,
95% CI 0.57–2.66; p = 0.605). Further analysis revealed thatTable 2
Relationship between anti-P. aeruginosa IgG and IgA titres and demographic
and clinical parameters.
Age FEV1 BMI WCC NEUT CRP
a
IgG a
r-Value −0.175 −0.429 −0.336 0.369 0.365 0.671
p-Value 0.252 0.003 0.024 0.013 0.014 b0.001
IgA a
r-Value −0.065 −0.237 −0.279 0.166 0.236 0.396
p-Value 0.673 0.117 0.063 0.274 0.119 0.007
FEV1: forced expiratory volume in one second; BMI: body mass index; WCC:
white cell count; NEUT: neutrophils; CRP: C-reactive protein.
a IgG, IgA and CRP were log transformed to achieve approximate normal
distribution of data.adjusting for lung function (OR = 1.19, 95% CI 0.57–2.46; p =
0.642) largely accounted for the observed loss of association. We
also examined survival trend across per 10-fold increase in IgG.
There was a significant association between IgG titre and mortality
(OR = 3.14, 95% CI 1.78–5.54; p b 0.001) which was no longer
apparent following adjustment for confounders (OR = 1.75, 95%
CI 0.95–3.22; p = 0.072). This loss of association was primarily
due to lung function (OR = 1.70, 95% CI 0.95–3.03; p = 0.072),
although some residual effect cannot be discounted.3.4. Antibody titre and sputum host inflammatory mediators
Sputum inflammatory biomarkers were available for the
Manchester patient group only (n = 40 patients). All results
were log transformed to achieve normal distribution of data. By
univariate analysis (Pearson's correlation coefficient), IgG and
IL-6, TNFα and TNFr1 were related (Table 3). In contrast, IgA
titres were related to IL-8, cathepsin S and cathepsin B (Table 3).
Cox proportional hazard modelling (Table 4) revealed evidence
of an association between IL-6 and survival (p = 0.035) but
no evidence of association between other sputum inflammatory
biomarkers and survival.4. Discussion
Our long-term study investigated the relationship between
anti-pseudomonal titre and mortality in CF patients. Whilst
univariate data analysis showed a significant difference in IgG
titre between P. aeruginosa patients still surviving and those
who had died, or had undergone lung transplantation, multivariate
analysis demonstrated that the relationship observed between IgG
and mortality was explained by decreased lung function (FEV1)
alone. In a 30-year cohort study, it was reported that CF patients
who are treated intensively have lower antibody responses and
longer survival after acquisition of chronic P. aeruginosa lung
infection [17]. Based on our findings, the longer survival observed
in this 30 year study may be due to a subsequent improve-
ment in lung function following intensive treatments rather
















































Fig. 2. Comparison of (A) serum IgG and (B) serum IgA titre in healthy control subjects (n = 118), P. aeruginosa negative CF patients (PA − ve, n = 36) and patients
chronically colonised with P. aeruginosa (PA + ve, n = 67). Mean and (95% CI) values for IgG are: control: 24.29 (21.49–27.09); PA − ve: 35.26 (22.35–48.16);
PA + ve: 349.7 (246.2–453.2) and for IgA: control: 12.20 (10.01–14.39); PA − ve: 37.03 (4.12–69.94); PA + ve: 381.2 (−13.74–776.2).
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with survival.
In addition to mortality, we investigated the relationship
between antibody titre and inflammatory mediators. Airway
inflammation is a major factor in the pathogenesis of CF lung
disease and inflammatory mediators as markers of the host
response to infection may reflect the intensity of lung injury
and relate to changes in clinical status. Our findings report
for the first time a significant positive correlation between
antipseudomonal IgG and IL-6, TNFα, and TNFr1, whilst
antipseudomonal IgA demonstrated a positive correlation
with IL8 and the lysosomal cysteine proteases cathepsin S
and cathepsin B. Cathepsin S has an important role in antigen
presentation but, in addition to cathepsin B, it also utilises a
number of extracellular matrix components as substrates thus
contributing to the destruction of the lung milieu. This is of
particular note as recently cathepsin S and B have been shown to
play important roles in the pathophysiology of CF lung disease
[4,22]. Correlations observed between IgG and IL-6, TNFα and
TNFr1 further highlight interactions between immunological and
inflammatory mediators following bacterial challenge within the
airways. Microbial secretions from P. aeruginosa, in addition to
its adherence to the epithelial lining of the respiratory tracts,IgG ≥ 110 (   ):
Numbers at risk by group
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Fig. 3. Kaplan–Meier plot illustrating survival in two groups defined by the
median IgG (110 ELISA units) with patients grouped using a categorical variable
above and below 110.induce IL-6 release from pulmonary epithelial cells. This is
further augmented by the release of TNFα from macrophages.
IL-6 acts as an inducer of the acute phase immune response to
infection by driving the proliferation and differentiation of beta
cells and subsequent immunoglobulin production. Other studies
demonstrate that IL-6 strongly enhances IgG and IgA secretion
by human lymphocytes following stimulation with bacteria [23].
Surprisingly, we did not observe any correlations between IgG
and IL-8 or NE. This may be due to the fact that IL-8 and NE are
secreted at the beginning of a pro-inflammatory response to
bacterial invasion with a systemic release of IgG occurring
downstream at a later time-point. A strong correlation was
observed between IgG and IgA in all samples suggesting the
inclusion of IgA in preliminary host defence during P. aeruginosa
invasion and colonisation. Bacterial challenge induces the
secretion of IgA within the pulmonary mucosa where it prevents
bacterial adhesion to surface epithelium, reduces bacterial growth
rate and neutralises bacterial exotoxins [24–26]. Should this
response be inadequate, IgG antibodies are subsequently produced
which pass into respiratory fluids or serum [24,27]. CF patients
with IgA deficiency can be rendered particularly susceptible to
infection [28].
We found significant differences between IgG and IgA titres
in both our control and CF patients. The residual level observed
within the control subjects can be attributed to ‘normal acquiredTable 3
Relationship between anti-P. aeruginosa IgG and IgA titres and sputum
inflammatory biomarkers.
Il-6 IL-8 TNFα TNFR1 HNE CAT S CAT B
IgG
r-Value 0.646 0.214 0.564 0.448 0.273 0.136 0.208
p-Value b0.001 0.180 0.001 0.004 0.084 0.397 0.397
IgA
r-Value 0.219 0.397 0.344 0.278 0.280 0.556 0.590
p-Value 0.168 0.010 0.054 0.087 0.076 b0.001 b0.001
HNE: Human Neutrophil Elastase; CAT S: Cathepsin S; CAT B: Cathepsin B.
IgG, IgA and all biomarker results were log transformed to achieve approximate
normal distribution of data.
Table 4
Relationship between sputum inflammatory biomarkers and survival.
Biomarker a Hazard ratio (95% CI) p-Value
IL-6 (per 10 fold increase) 5.80 (1.13, 29.61) 0.035
IL-8 (per 10 fold increase) 1.84 (0.52, 6.55) 0.348
TNFα (per 10 fold increase) 1.87 (0.67, 5.25) 0.234
TNFR1 (per 10 fold increase) 2.74 (0.60, 12.62) 0.195
HNE (per 10 fold increase) 4. 95 (0.46, 52.89) 0.186
CAT S (per 10 fold increase) 4.56 (0.61, 34.28) 0.140
CAT B (per 10 fold increase) 1.56 (0.47, 5.16) 0.465
HNE: Human Neutrophil Elastase; CAT S: Cathepsin S; CAT B: Cathepsin B.
a IgG and all biomarker results were log transformed (to base 10) to achieve
approximate normal distribution of data and consequently hazard ratios
presented are for a 10 fold increase in each variable.
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P. aeruginosa had higher IgG titres compared to those without
colonisation which is in agreement with previous studies [30].
Following P. aeruginosa infection, the humoral response leads
to an increase in the formation and accumulation of immune
complexes. These may contribute to severe pulmonary disease
in the CF lung and further formation of chronic P. aeruginosa
infections [31,32].
Over several decades there has been much research and
speculation into the role of antibody titres to P. aeruginosa and
clinical status. Measurement of serum IgG antibodies by ELISA
provides a specific, quantitative and highly sensitive measure of
immunological changes associated with all stages of pulmonary
infection by P. aeruginosa. These changes correlate with a
decline in clinical state and lung function [33]. Our findings
demonstrate positive correlations between IgG and several
clinical and immunological parameters which further support
this view. However, the results should be interpreted with caution
as we have established that the association between IgG and
mortality can be explained by a decline in lung function.
Furthermore, our results are based on cross-sectional data and
patients who were P. aeruginosa negative at the time of sample
collection may change in due course to P. aeruginosa positive.
Detection of anti-pseudomonal IgG or IgA antibodies in serum
has been reported to precede isolation of P. aeruginosa by routine
microbial culture [14,17]. Brett et al. reported that 90% of CF
patients produced specific IgA antibodies before the organism was
present in sufficient numbers to be isolated from the respiratory
tract [28]. However, the reliability and usefulness of titres are
questionable as antibody variance amongst infected patients
occurs; some patients show an increase in P. aeruginosa specific
antibodies shortly after these organisms are cultured whereas
other patients can be colonised for 1–2 years without eliciting
any systemic immune response [29]. In addition, discrepancies
may occur due to the choice of antigenic preparation used in
ELISA systems and variability in microbiological culture facilities.
The associated host immunological response includes the release
of antibodies against a variety of pseudomonal antigens. Whilst
many of these are detected in CF patients, no single antigen has
been found to detect an antibody response in all CF patients.
Nevertheless, it is vital to establish as soon as possible when
P. aeruginosa colonisation elicits a systemic immune response
and subsequent tissue damage. In patients chronically infectedwith P. aeruginosa, a large and sudden increase in antibody
titre is a poor prognostic factor with an increase in IgG titre
correlating with a decrease in lung function and poor clinical
condition [5,8,33]. Our study highlights the association of
anti-pseudomonal immunological titres with both clinical param-
eters and inflammatory biomarkers.
We have demonstrated that IgG is particularly relevant
in chronic P. aeruginosa infection. Furthermore, in addition to
a correlation with IgG, anti-pseudomonal IgA also correlated
with the pro-inflammatory biomarkers CRP, IL-8 and cathepsins
S and B. Although important in host defence against respiratory
viruses, IgAmay be less important in bacterial infections; however,
measuring specific IgA titres fromP. aeruginosamay be useful for
differentiating between active infection and colonisation [28,34].
Some transmissible strains of P. aeruginosa are more virulent
that non-transmissible strains, especially within the CF popula-
tion. Previous studies have shown no difference in inflammatory
markers in patients chronically infected with both strains or
indeed in their clinical outcome [3,35]. Our findings, which also
show no difference between anti-pseudomonal titre in patients
chronically infected with either transmissible or sporadic strains
of P. aeruginosa, further supports this view.5. Conclusion
We have demonstrated a relationship between anti-
pseudomonal IgG and IgA titres and other systemic markers
of inflammation. During periods of clinical stability, CF
patients infected with transmissible P. aeruginosa did not show a
heightened IgG or IgA response against specific P. aeruginosa
antigens, when compared with patients colonised with non-
transmissible strains. This is in agreement with previous findings
that demonstrate no difference in inflammatory response between
these two groups. The univariate correlation between IgG and
10 year survival was explained by a decrease in FEV1 rather than
an increase in anti-pseudomonal antibodies. In addition, pro-
inflammatory mediators correlated with IgG response suggest
that the IgG response to P. aeruginosa can be an immunological
marker of chronic infection and declining lung function but cannot
be used to predict survival outcome.Funding
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